News

Radius Files Definitive Proxy and Mails Letter to Stockholders

Urges Stockholders to Vote “FOR” Radius’ Highly Qualified, Independent Director Nominees – Catherine J. Friedman, Jean-Pierre Garnier, Ph.D. and Andrew…

2 years ago

Quipt Home Medical on Preliminary List to Join Russell Microcap® Index

CINCINNATI, June 06, 2022 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ:QIPT; TSXV:QIPT), a U.S. based…

2 years ago

Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease

Cambridge, Mass. and Burnaby, British Columbia , June 06, 2022 (GLOBE NEWSWIRE) -- Biogen and Alectos Therapeutics Announce License and…

2 years ago

Arcutis Announces Positive Topline Results from STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis

Study met its primary endpoint with 80.1% of individuals treated with roflumilast foam achieving Investigator Global Assessment (IGA) Success compared…

2 years ago

Red Light Holland Psilocybin Truffles, Sold in The Netherlands, Complete First Stability Test Under a Health Canada Approved cGMP Laboratory

Red Light Holland's iMicrodose packs containing Psilocybe Tampanensis Truffles, produced in the Netherlands, tested at CCrest Laboratories, under a Health…

2 years ago

Establishment Labs to Present at the Jefferies Healthcare Conference

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and…

2 years ago

SleepScore Labs Unveils Latest Findings From 14 New Studies at SLEEP 2022 Conference

Research leveraging SleepScore’s expansive data collection advances science of sleep health across wide variety of themes. CARLSBAD, Calif.--(BUSINESS WIRE)--SleepScore Labs,…

2 years ago

HOOKIPA announces positive Phase 1 data and Phase 2 plans for HB-200 program for the treatment of advanced head and neck cancers at ASCO

Alternating 2-vector therapy showed superior antigen-specific T cell responses, more robust anti-tumor activity and similar tolerability vs. single-vector therapyPhase 2…

2 years ago

Clover Provides Update on 2022 Corporate Milestones

-- Changxing manufacturing facility readiness and CMC activities impacted by COVID-19 outbreak in China - the facility is now expected…

2 years ago

Centessa Pharmaceuticals Announces Poster Presentation of First Preclinical Data for LockBody® Program at 2022 ASCO Annual Meeting

Preclinical data showed that single-agent LB101, PD-L1xCD47 LockBody, delivered systemically led to meaningful tumor regressions and was well toleratedBOSTON and…

2 years ago